The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study

  • Arwa Younis, Dana Eskenazi, Ronen Goldkorn, Jonathan Leor, Nili Naftali-Shani, Enrique Z. Fisman, Alexander Tenenbaum, Ilan Goldenberg, Robert Klempfner
  • Cardiovascular Diabetology, May 2017, Springer Science + Business Media
  • DOI: 10.1186/s12933-017-0551-5

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1186/s12933-017-0551-5

The following have contributed to this page: Dr Nili Naftali-Shani